This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eisai Co., Ltd.
Drug Names(s): L-glutamine, E6014
Saforis is an oral suspension of L-glutamine in a proprietary delivery vehicle designed to increase uptake of glutamine by the oral mucosa. Glutamine is an amino acid essential in the healing and regeneration of mucosal cells.
L-glutamine is required in the last step of NAD synthesis, where it is an amide donor for NAD synthetase
Deal Structure: Saforis was originally developed by Aesgen, Inc., an independent privately-held pharmaceutical company founded in 1994.
In September 2004, MGI Pharma and Aesgen signed a definitive merger agreement under which MGI Pharma agreed to acquire all outstanding equity of Aesgen for $32 million in cash. MGI Pharma may also be obligated to make performance milestone payments of $33 million upon regulatory approval and $25 million if sales exceed $50 million in the second year following product launch. In addition, MGI Pharma will pay a 5% royalty on product sales.
In December 2007, Eisai and MGI Pharma announced that they entered into a definitive merger agreement under which Eisai would acquire all of the outstanding shares of MGI Pharma for US$41.00 per share in an all cash transaction, for a total consideration of approximately $3.9 billion.
Pink Sheet Saforis Granted Priority Review
Pink Sheet ‘Complete Response’ Letters
Additional information available to subscribers only: